

Liraglutide tops lixisenatide as add-on to metformin in T2DM

28 June 2016



(HealthDay)—For patients with type 2 diabetes taking metformin, add-on liraglutide is more effective than lixisenatide for improving glycemic control, according to a study published online June 16 in *Diabetes Care*.

Michael Nauck, M.D., from the Ruhr-University Bochum in Germany, and colleagues conducted a 26-week randomized trial involving 404 [patients](#) with type 2 [diabetes](#) not achieving adequate glycemic control on metformin alone. Participants were randomized in a 1:1 ratio to liraglutide (administered once daily at any time of the day) or lixisenatide (administered once daily within one hour prior to morning or evening meal).

The researchers found that hemoglobin A1c (HbA1c) was reduced more with liraglutide than lixisenatide at week 26 (estimated treatment difference ?0.62 percent; $P < 0.0001$), with more patients reaching HbA1c

APA citation: Liraglutide tops lixisenatide as add-on to metformin in T2DM (2016, June 28) retrieved 21 April 2021 from <https://medicalxpress.com/news/2016-06-liraglutide-tops-lixisenatide-add-on-metformin.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.